Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-BCMA/FcRL5 CAR-T in Relapsed and Refractory Multiple Myeloma
NCT06759181Phase 2Recruiting
- Sponsor
- Xuzhou Medical University
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 2 trial of anti-BCMA/FcRL5 CAR-T cell therapy in multiple myeloma (MM), sponsored by Xuzhou Medical University. Started Dec 2024; status: recruiting.
02
Drugs
anti-BCMA/FcRL5 CAR-T cell therapy
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06759181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06759181.